Trial Outcomes & Findings for A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors (NCT NCT04393298)
NCT ID: NCT04393298
Last Updated: 2025-05-29
Results Overview
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study medication. A treatment-emergent adverse event (TEAE) was defined as any AE with a start date on or after the first dose of UCB6114 up until the last dose of Ginisortamab (UCB6114) +30 days (i.e. up to 3.8 years).
Recruitment status
COMPLETED
Study phase
PHASE1/PHASE2
Target enrollment
93 participants
Primary outcome timeframe
From Baseline until the End of Study (up to 3.8 years)
Results posted on
2025-05-29
Participant Flow
The study started to enroll participants in July 2020 and concluded in April 2024.
The Participant Flow refers to the Safety Set (SS).
Participant milestones
| Measure |
Part A: Ginisortamab 100 mg
Participants received ginisortamab monotherapy 100 milligrams (mg) as an intravenously (iv) infusion every 2 weeks (Q2W) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 250 mg
Participants received ginisortamab monotherapy 250 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 500 mg
Participants received ginisortamab monotherapy 500 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 1000 mg
Participants received ginisortamab monotherapy 1000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 2000 mg
Participants received ginisortamab monotherapy 2000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (60-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (30-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D
Participants received ginisortamab monotherapy 3000 mg as an iv infusion (90-minute infusion) every 3 weeks (Q3W) on Day 1 of each 21-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D
Participants received ginisortamab monotherapy 4000 mg as an iv infusion (120-minute infusion) every 4 weeks (Q4W) on Day 1 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 500 mg + TFD/TPI SoC
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with orally administered trifluridine/tipiracil (TFD/TPI) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 1000 mg + TFD/TPI SoC
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 2000 mg + TFD/TPI SoC
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 500 mg + mFOLFOX6 SoC
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
3
|
5
|
5
|
6
|
6
|
8
|
8
|
8
|
8
|
9
|
4
|
8
|
5
|
3
|
7
|
|
Overall Study
COMPLETED
|
1
|
1
|
2
|
3
|
3
|
1
|
4
|
5
|
2
|
5
|
3
|
3
|
3
|
2
|
0
|
|
Overall Study
NOT COMPLETED
|
2
|
4
|
3
|
3
|
3
|
7
|
4
|
3
|
6
|
4
|
1
|
5
|
2
|
1
|
7
|
Reasons for withdrawal
| Measure |
Part A: Ginisortamab 100 mg
Participants received ginisortamab monotherapy 100 milligrams (mg) as an intravenously (iv) infusion every 2 weeks (Q2W) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 250 mg
Participants received ginisortamab monotherapy 250 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 500 mg
Participants received ginisortamab monotherapy 500 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 1000 mg
Participants received ginisortamab monotherapy 1000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 2000 mg
Participants received ginisortamab monotherapy 2000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (60-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (30-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D
Participants received ginisortamab monotherapy 3000 mg as an iv infusion (90-minute infusion) every 3 weeks (Q3W) on Day 1 of each 21-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D
Participants received ginisortamab monotherapy 4000 mg as an iv infusion (120-minute infusion) every 4 weeks (Q4W) on Day 1 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 500 mg + TFD/TPI SoC
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with orally administered trifluridine/tipiracil (TFD/TPI) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 1000 mg + TFD/TPI SoC
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 2000 mg + TFD/TPI SoC
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 500 mg + mFOLFOX6 SoC
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
Adverse Event
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
1
|
1
|
0
|
|
Overall Study
Consent withdrawn by participant, not due to AE
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
|
Overall Study
Lack of Efficacy
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
Overall Study
Progression
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
|
Overall Study
Passed Away on The 30 Oct 2020
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Disease Progression Confirmed by Scans (CT/MRI)
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Clinical Progression
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Disease Progression
|
0
|
1
|
0
|
0
|
0
|
3
|
2
|
1
|
2
|
1
|
0
|
3
|
0
|
0
|
1
|
|
Overall Study
Since no Treatment Administered at Cycle 2 Day 15
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Further Deterioration Noted at Clinic review
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Progressive Disease (PD)
|
0
|
0
|
0
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Started a New Cancer Treatment
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Sponsor decision- sepsis (treatment delay)
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Due to symptoms (New Brain Metastases)
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Clinical Progression: Not suitable for SFU return
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
Overall Study
Death
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
1
|
1
|
0
|
1
|
1
|
0
|
1
|
|
Overall Study
Progressive Disease - New Brain Mets on CT Head
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Progressive Disease and Subsequent Death
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Patient Passed Away
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Patient Deceased
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Patient Discharged to Hospice
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Symptomatic Cancer - Unfit to take a call
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Clinical Progression in Combination with AE
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
Baseline Characteristics
A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors
Baseline characteristics by cohort
| Measure |
Part A: Ginisortamab 100 mg
n=3 Participants
Participants received ginisortamab monotherapy 100 milligrams (mg) as an intravenously (iv) infusion every 2 weeks (Q2W) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 250 mg
n=5 Participants
Participants received ginisortamab monotherapy 250 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 500 mg
n=5 Participants
Participants received ginisortamab monotherapy 500 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 1000 mg
n=6 Participants
Participants received ginisortamab monotherapy 1000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 2000 mg
n=6 Participants
Participants received ginisortamab monotherapy 2000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D
n=8 Participants
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (60-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D
n=8 Participants
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (30-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D
n=8 Participants
Participants received ginisortamab monotherapy 3000 mg as an iv infusion (90-minute infusion) every 3 weeks (Q3W) on Day 1 of each 21-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D
n=8 Participants
Participants received ginisortamab monotherapy 4000 mg as an iv infusion (120-minute infusion) every 4 weeks (Q4W) on Day 1 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 500 mg + TFD/TPI SoC
n=9 Participants
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with orally administered trifluridine/tipiracil (TFD/TPI) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 1000 mg + TFD/TPI SoC
n=4 Participants
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 2000 mg + TFD/TPI SoC
n=8 Participants
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 500 mg + mFOLFOX6 SoC
n=5 Participants
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC
n=3 Participants
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC
n=7 Participants
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Total
n=93 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
65.0 Years
STANDARD_DEVIATION 1.0 • n=5 Participants
|
54.4 Years
STANDARD_DEVIATION 11.0 • n=7 Participants
|
58.2 Years
STANDARD_DEVIATION 12.2 • n=5 Participants
|
65.3 Years
STANDARD_DEVIATION 8.0 • n=4 Participants
|
60.7 Years
STANDARD_DEVIATION 9.5 • n=21 Participants
|
56.6 Years
STANDARD_DEVIATION 12.0 • n=8 Participants
|
67.3 Years
STANDARD_DEVIATION 6.3 • n=8 Participants
|
60.9 Years
STANDARD_DEVIATION 6.7 • n=24 Participants
|
60.8 Years
STANDARD_DEVIATION 17.6 • n=42 Participants
|
57.6 Years
STANDARD_DEVIATION 9.5 • n=42 Participants
|
51.5 Years
STANDARD_DEVIATION 6.2 • n=42 Participants
|
57.6 Years
STANDARD_DEVIATION 14.2 • n=42 Participants
|
58.6 Years
STANDARD_DEVIATION 10.7 • n=36 Participants
|
63.0 Years
STANDARD_DEVIATION 13.0 • n=36 Participants
|
61.1 Years
STANDARD_DEVIATION 9.1 • n=24 Participants
|
59.9 Years
STANDARD_DEVIATION 10.7 • n=135 Participants
|
|
Age, Customized
18 - <65 years
|
1 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
3 Participants
n=21 Participants
|
7 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
5 Participants
n=24 Participants
|
4 Participants
n=42 Participants
|
7 Participants
n=42 Participants
|
4 Participants
n=42 Participants
|
7 Participants
n=42 Participants
|
3 Participants
n=36 Participants
|
2 Participants
n=36 Participants
|
5 Participants
n=24 Participants
|
61 Participants
n=135 Participants
|
|
Age, Customized
65 - <85 years
|
2 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
3 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
5 Participants
n=8 Participants
|
3 Participants
n=24 Participants
|
4 Participants
n=42 Participants
|
2 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
2 Participants
n=36 Participants
|
1 Participants
n=36 Participants
|
2 Participants
n=24 Participants
|
32 Participants
n=135 Participants
|
|
Sex: Female, Male
Female
|
0 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
3 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
5 Participants
n=24 Participants
|
2 Participants
n=42 Participants
|
4 Participants
n=42 Participants
|
2 Participants
n=42 Participants
|
2 Participants
n=42 Participants
|
2 Participants
n=36 Participants
|
1 Participants
n=36 Participants
|
3 Participants
n=24 Participants
|
35 Participants
n=135 Participants
|
|
Sex: Female, Male
Male
|
3 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
4 Participants
n=4 Participants
|
5 Participants
n=21 Participants
|
5 Participants
n=8 Participants
|
5 Participants
n=8 Participants
|
3 Participants
n=24 Participants
|
6 Participants
n=42 Participants
|
5 Participants
n=42 Participants
|
2 Participants
n=42 Participants
|
6 Participants
n=42 Participants
|
3 Participants
n=36 Participants
|
2 Participants
n=36 Participants
|
4 Participants
n=24 Participants
|
58 Participants
n=135 Participants
|
|
Race/Ethnicity, Customized
Asian
|
0 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
1 Participants
n=36 Participants
|
1 Participants
n=24 Participants
|
4 Participants
n=135 Participants
|
|
Race/Ethnicity, Customized
Black or African American
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
3 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
1 Participants
n=36 Participants
|
1 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
6 Participants
n=135 Participants
|
|
Race/Ethnicity, Customized
White
|
3 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
4 Participants
n=5 Participants
|
6 Participants
n=4 Participants
|
6 Participants
n=21 Participants
|
8 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
8 Participants
n=24 Participants
|
8 Participants
n=42 Participants
|
6 Participants
n=42 Participants
|
3 Participants
n=42 Participants
|
8 Participants
n=42 Participants
|
4 Participants
n=36 Participants
|
1 Participants
n=36 Participants
|
5 Participants
n=24 Participants
|
82 Participants
n=135 Participants
|
|
Race/Ethnicity, Customized
Other/Mixed
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
1 Participants
n=24 Participants
|
1 Participants
n=135 Participants
|
|
Race/Ethnicity, Customized
Not Hispanic or Latino
|
3 Participants
n=5 Participants
|
5 Participants
n=7 Participants
|
5 Participants
n=5 Participants
|
6 Participants
n=4 Participants
|
6 Participants
n=21 Participants
|
8 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
8 Participants
n=24 Participants
|
8 Participants
n=42 Participants
|
9 Participants
n=42 Participants
|
4 Participants
n=42 Participants
|
8 Participants
n=42 Participants
|
5 Participants
n=36 Participants
|
3 Participants
n=36 Participants
|
7 Participants
n=24 Participants
|
93 Participants
n=135 Participants
|
PRIMARY outcome
Timeframe: From Baseline until the End of Study (up to 3.8 years)Population: The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study medication. A treatment-emergent adverse event (TEAE) was defined as any AE with a start date on or after the first dose of UCB6114 up until the last dose of Ginisortamab (UCB6114) +30 days (i.e. up to 3.8 years).
Outcome measures
| Measure |
Part A: Ginisortamab 100 mg
n=3 Participants
Participants received ginisortamab monotherapy 100 milligrams (mg) as an intravenously (iv) infusion every 2 weeks (Q2W) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 250 mg
n=5 Participants
Participants received ginisortamab monotherapy 250 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 500 mg
n=5 Participants
Participants received ginisortamab monotherapy 500 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 1000 mg
n=6 Participants
Participants received ginisortamab monotherapy 1000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 2000 mg
n=6 Participants
Participants received ginisortamab monotherapy 2000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D
n=8 Participants
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (60-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D
n=8 Participants
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (30-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D
n=8 Participants
Participants received ginisortamab monotherapy 3000 mg as an iv infusion (90-minute infusion) every 3 weeks (Q3W) on Day 1 of each 21-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D
n=8 Participants
Participants received ginisortamab monotherapy 4000 mg as an iv infusion (120-minute infusion) every 4 weeks (Q4W) on Day 1 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 500 mg + TFD/TPI SoC
n=9 Participants
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with orally administered trifluridine/tipiracil (TFD/TPI) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 1000 mg + TFD/TPI SoC
n=4 Participants
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 2000 mg + TFD/TPI SoC
n=8 Participants
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 500 mg + mFOLFOX6 SoC
n=5 Participants
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC
n=3 Participants
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC
n=7 Participants
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
|
100 percentage of participants
|
100 percentage of participants
|
100 percentage of participants
|
100 percentage of participants
|
100 percentage of participants
|
87.5 percentage of participants
|
100 percentage of participants
|
87.5 percentage of participants
|
100 percentage of participants
|
100 percentage of participants
|
100 percentage of participants
|
100 percentage of participants
|
100 percentage of participants
|
100 percentage of participants
|
100 percentage of participants
|
PRIMARY outcome
Timeframe: From Baseline until the End of Study (up to 3.8 years)Population: The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
AE is any untoward medical occurrence in patient or clinical study participant, temporally associated with use of study medication, whether or not considered related to study medication. AE can therefore be any unfavorable and unintended sign (including abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with use of study medication. TEAE: any AE with start date on or after first dose of UCB6114 up until last dose of Ginisortamab(UCB6114)+30 days. Event for which no Common Terminology Criteria for AE (CTCAE) severity grade was recorded by investigator but intensity was recorded instead was assigned as follows to CTCAE severity grade:Severe=Grade 3, Life Threatening (indicated on electronic case report form (eCRF) for event that is serious)=Grade 4, Death (indicated on the eCRF for event that is serious or has outcome of death)=Grade 5. As planned, data reported for National Cancer Institute (NCI) CTCAE grade \>=3 TEAEs and related TEAEs.
Outcome measures
| Measure |
Part A: Ginisortamab 100 mg
n=3 Participants
Participants received ginisortamab monotherapy 100 milligrams (mg) as an intravenously (iv) infusion every 2 weeks (Q2W) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 250 mg
n=5 Participants
Participants received ginisortamab monotherapy 250 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 500 mg
n=5 Participants
Participants received ginisortamab monotherapy 500 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 1000 mg
n=6 Participants
Participants received ginisortamab monotherapy 1000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 2000 mg
n=6 Participants
Participants received ginisortamab monotherapy 2000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D
n=8 Participants
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (60-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D
n=8 Participants
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (30-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D
n=8 Participants
Participants received ginisortamab monotherapy 3000 mg as an iv infusion (90-minute infusion) every 3 weeks (Q3W) on Day 1 of each 21-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D
n=8 Participants
Participants received ginisortamab monotherapy 4000 mg as an iv infusion (120-minute infusion) every 4 weeks (Q4W) on Day 1 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 500 mg + TFD/TPI SoC
n=9 Participants
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with orally administered trifluridine/tipiracil (TFD/TPI) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 1000 mg + TFD/TPI SoC
n=4 Participants
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 2000 mg + TFD/TPI SoC
n=8 Participants
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 500 mg + mFOLFOX6 SoC
n=5 Participants
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC
n=3 Participants
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC
n=7 Participants
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Percentage of Participants Based on Severity of Treatment-emergent Adverse Events
NCI CTCAE grade >=3 TEAEs
|
66.7 percentage of participants
|
40.0 percentage of participants
|
40.0 percentage of participants
|
0 percentage of participants
|
50.0 percentage of participants
|
62.5 percentage of participants
|
50.0 percentage of participants
|
37.5 percentage of participants
|
62.5 percentage of participants
|
55.6 percentage of participants
|
75.0 percentage of participants
|
87.5 percentage of participants
|
100 percentage of participants
|
100 percentage of participants
|
85.7 percentage of participants
|
|
Percentage of Participants Based on Severity of Treatment-emergent Adverse Events
NCI CTCAE grade >=3 related TEAEs
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
12.5 percentage of participants
|
22.2 percentage of participants
|
0 percentage of participants
|
25.0 percentage of participants
|
40.0 percentage of participants
|
0 percentage of participants
|
14.3 percentage of participants
|
PRIMARY outcome
Timeframe: From Baseline throughout 28 days (Cycle 1)Population: The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
DLT defined as any AE at least related to study medication that occurs during Cycle 1 and met following criteria: Grade (Gr) 3 or 4 nonhematological toxicity according to NCI CTCAE (Version 5.0) except for alopecia, or nausea, vomiting, or diarrhea that reverses to Gr ≤2 within 24 hours (hr) with appropriate medical therapy; Gr 3 or 4 biochemical abnormality that persists despite maximal supportive treatment or biochemical abnormalities that is symptomatic and nontransient; Any Gr ≥3 hematological toxicity of \>5 days duration or febrile neutropenia (absolute neutrophil count \[ANC\]\<1000/cubic millimeter\[mm3\] with single temperature of \>38.3°C or sustained temperature ≥38°C for more than one hr), infection with Gr 3 or 4 neutropenia, thrombocytopenia with bleeding or requiring platelet transfusion, or Gr 4 thrombocytopenia; Prolonged Gr 2 diarrhea (\>7 days) despite adequate antidiarrheal medication, or multiple Grade 1or 2 toxicities(eg, Gr 1 or 2 diarrhea, vomiting, rash, and fatigue).
Outcome measures
| Measure |
Part A: Ginisortamab 100 mg
n=3 Participants
Participants received ginisortamab monotherapy 100 milligrams (mg) as an intravenously (iv) infusion every 2 weeks (Q2W) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 250 mg
n=5 Participants
Participants received ginisortamab monotherapy 250 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 500 mg
n=5 Participants
Participants received ginisortamab monotherapy 500 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 1000 mg
n=6 Participants
Participants received ginisortamab monotherapy 1000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 2000 mg
n=6 Participants
Participants received ginisortamab monotherapy 2000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D
n=8 Participants
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (60-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D
n=8 Participants
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (30-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D
n=8 Participants
Participants received ginisortamab monotherapy 3000 mg as an iv infusion (90-minute infusion) every 3 weeks (Q3W) on Day 1 of each 21-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D
n=8 Participants
Participants received ginisortamab monotherapy 4000 mg as an iv infusion (120-minute infusion) every 4 weeks (Q4W) on Day 1 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 500 mg + TFD/TPI SoC
n=9 Participants
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with orally administered trifluridine/tipiracil (TFD/TPI) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 1000 mg + TFD/TPI SoC
n=4 Participants
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 2000 mg + TFD/TPI SoC
n=8 Participants
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 500 mg + mFOLFOX6 SoC
n=5 Participants
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC
n=3 Participants
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC
n=7 Participants
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Dose-limiting Toxicities (DLTs)
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Parts A: Cycle 1 (Day 1 end of infusion [EOI] and Day 15 Predose), Cycle 2 (Day 1 Predose and Day 15 Predose); Part A 1: Cycle 1 (Day 1 EOI and Day 15 Predose), Cycle 2 (Day 1 Predose)Population: PKS:all participants of SS with \>=1 evaluable PKS concentration (ie, sample above LLOQ\[0.02μg/mL\] and for which date, sample time, prior date dosing time are known). Number analyzed:participants evaluable at specified time points. Dosing was only performed on Day 1 of each cycle for Part A1:Ginisortamab 3000mg Q3W(90-min) 21-day and Ginisortamab 4000mg Q4W(120-min) 28-day arms. Hence, Predose, Day 15 of Cycle 1 was not collected. No arms of Part A1 had data collection on Cycle 2 Day 15 Predose.
Blood samples for ginisortamab serum concentration analysis were collected at different timepoints following the first dose of ginisortamab. The data is reported for Part A and A1. Pharmacokinetic Set (PKS). Lower Limit of Quantitation (LLOQ).
Outcome measures
| Measure |
Part A: Ginisortamab 100 mg
n=3 Participants
Participants received ginisortamab monotherapy 100 milligrams (mg) as an intravenously (iv) infusion every 2 weeks (Q2W) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 250 mg
n=5 Participants
Participants received ginisortamab monotherapy 250 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 500 mg
n=5 Participants
Participants received ginisortamab monotherapy 500 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 1000 mg
n=6 Participants
Participants received ginisortamab monotherapy 1000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 2000 mg
n=6 Participants
Participants received ginisortamab monotherapy 2000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D
n=8 Participants
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (60-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D
n=8 Participants
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (30-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D
n=8 Participants
Participants received ginisortamab monotherapy 3000 mg as an iv infusion (90-minute infusion) every 3 weeks (Q3W) on Day 1 of each 21-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D
n=8 Participants
Participants received ginisortamab monotherapy 4000 mg as an iv infusion (120-minute infusion) every 4 weeks (Q4W) on Day 1 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 500 mg + TFD/TPI SoC
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with orally administered trifluridine/tipiracil (TFD/TPI) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 1000 mg + TFD/TPI SoC
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 2000 mg + TFD/TPI SoC
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 500 mg + mFOLFOX6 SoC
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Part A and A1: UCB6114 Serum Concentration by Scheduled Assessment and Cohort
Cycle 1 Day 1 EOI
|
18.0477 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 10.0206
|
72.5261 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 24.1924
|
130.7757 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 14.1088
|
277.5536 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 10.8287
|
552.3530 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 19.5548
|
592.2331 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 26.1556
|
593.1846 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 22.2154
|
946.0883 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 19.3798
|
1357.6103 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 20.4135
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Part A and A1: UCB6114 Serum Concentration by Scheduled Assessment and Cohort
Cycle 1 Day 15 Predose
|
4.4210 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 10.1288
|
12.8115 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 27.1385
|
24.3743 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 31.2011
|
61.4527 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 33.1491
|
92.0396 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 38.4595
|
105.5277 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 25.1756
|
97.1957 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 39.3439
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Part A and A1: UCB6114 Serum Concentration by Scheduled Assessment and Cohort
Cycle 2 Day 1 Predose
|
NA microgram per milliliter (ug/mL)
Geometric Coefficient of Variation NA
GeoMean and GeoCV (%) were only calculated if at least 2/3 of the concentrations are quantified at the respective timepoint.
|
NA microgram per milliliter (ug/mL)
Geometric Coefficient of Variation NA
GeoMean and GeoCV (%) were only calculated if at least 2/3 of the concentrations are quantified at the respective timepoint.
|
34.6409 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 26.9986
|
67.0799 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 37.9557
|
149.3886 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 37.0769
|
193.4242 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 34.5942
|
147.2154 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 26.4979
|
124.7274 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 44.3198
|
98.9331 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 33.8567
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Part A and A1: UCB6114 Serum Concentration by Scheduled Assessment and Cohort
Cycle 2 Day 15 Predose
|
NA microgram per milliliter (ug/mL)
Geometric Coefficient of Variation NA
GeoMean and GeoCV (%) were only calculated if at least 2/3 of the concentrations are quantified at the respective timepoint.
|
NA microgram per milliliter (ug/mL)
Geometric Coefficient of Variation NA
GeoMean and GeoCV (%) were only calculated if at least 2/3 of the concentrations are quantified at the respective timepoint.
|
42.6861 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 38.1929
|
78.2336 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 35.0467
|
166.4011 microgram per milliliter (ug/mL)
Geometric Coefficient of Variation 34.1041
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Part B and C: Cycle 1 (Day 1 EOI and Day 15 Predose), Cycle 2 (Day 1 Predose and Day 15 Predose)Population: The PKS included all study participants in the SS (all study participants who received at least 1 full or partial dose of Ginisortamab \[UCB6114\]) who had at least 1 evaluable PKS concentration (ie, a sample which is above the lower limit of quantitation \[0.02μg/mL\] and for which the date and time of the sample and prior date and time of dosing are known). Here, number analyzed signifies participants who were evaluable at specified time points.
Blood samples for ginisortamab serum concentration analysis were collected at timepoints following (Cycle 1 Day 1) and the (Cycle 2 Day 1) administration of ginisortamab. Data is reported for Part B and Part C.
Outcome measures
| Measure |
Part A: Ginisortamab 100 mg
n=9 Participants
Participants received ginisortamab monotherapy 100 milligrams (mg) as an intravenously (iv) infusion every 2 weeks (Q2W) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 250 mg
n=4 Participants
Participants received ginisortamab monotherapy 250 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 500 mg
n=8 Participants
Participants received ginisortamab monotherapy 500 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 1000 mg
n=5 Participants
Participants received ginisortamab monotherapy 1000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 2000 mg
n=3 Participants
Participants received ginisortamab monotherapy 2000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D
n=7 Participants
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (60-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (30-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D
Participants received ginisortamab monotherapy 3000 mg as an iv infusion (90-minute infusion) every 3 weeks (Q3W) on Day 1 of each 21-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D
Participants received ginisortamab monotherapy 4000 mg as an iv infusion (120-minute infusion) every 4 weeks (Q4W) on Day 1 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 500 mg + TFD/TPI SoC
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with orally administered trifluridine/tipiracil (TFD/TPI) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 1000 mg + TFD/TPI SoC
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 2000 mg + TFD/TPI SoC
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 500 mg + mFOLFOX6 SoC
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Part B and C: UCB6114 Concentration by Scheduled Assessment and Dose Level
Cycle 2 Day 1 Predose
|
33.0061 ug/mL
Geometric Coefficient of Variation 35.3957
|
61.0398 ug/mL
Geometric Coefficient of Variation 5.0117
|
118.0926 ug/mL
Geometric Coefficient of Variation 29.3051
|
25.4863 ug/mL
Geometric Coefficient of Variation 53.6347
|
82.7657 ug/mL
Geometric Coefficient of Variation 47.9648
|
141.6084 ug/mL
Geometric Coefficient of Variation 30.8310
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Part B and C: UCB6114 Concentration by Scheduled Assessment and Dose Level
Cycle 1 Day 1 EOI
|
104.0606 ug/mL
Geometric Coefficient of Variation 15.3565
|
250.8708 ug/mL
Geometric Coefficient of Variation 7.6032
|
463.5265 ug/mL
Geometric Coefficient of Variation 28.6333
|
122.8221 ug/mL
Geometric Coefficient of Variation 14.8778
|
175.0745 ug/mL
Geometric Coefficient of Variation 34.7390
|
471.9576 ug/mL
Geometric Coefficient of Variation 17.1727
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Part B and C: UCB6114 Concentration by Scheduled Assessment and Dose Level
Cycle 1 Day 15 Predose
|
19.7473 ug/mL
Geometric Coefficient of Variation 42.6072
|
37.4171 ug/mL
Geometric Coefficient of Variation 14.8496
|
83.4236 ug/mL
Geometric Coefficient of Variation 30.8533
|
16.8917 ug/mL
Geometric Coefficient of Variation 33.2664
|
32.3094 ug/mL
Geometric Coefficient of Variation 56.2327
|
70.7026 ug/mL
Geometric Coefficient of Variation 50.9842
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Part B and C: UCB6114 Concentration by Scheduled Assessment and Dose Level
Cycle 2 Day 15 Predose
|
38.3595 ug/mL
Geometric Coefficient of Variation 42.1013
|
55.0249 ug/mL
Geometric Coefficient of Variation 39.4082
|
135.5849 ug/mL
Geometric Coefficient of Variation 32.8644
|
24.7120 ug/mL
Geometric Coefficient of Variation 83.6183
|
NA ug/mL
Geometric Coefficient of Variation NA
GeoMean and GeoCV (%) were only calculated if at least 2/3 of the concentrations are quantified at the respective timepoint.
|
135.0042 ug/mL
Geometric Coefficient of Variation 43.8716
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
Adverse Events
Part A: Ginisortamab 100 mg
Serious events: 2 serious events
Other events: 3 other events
Deaths: 1 deaths
Part A: Ginisortamab 250 mg
Serious events: 3 serious events
Other events: 5 other events
Deaths: 0 deaths
Part A: Ginisortamab 500 mg
Serious events: 1 serious events
Other events: 5 other events
Deaths: 0 deaths
Part A: Ginisortamab 1000 mg
Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths
Part A: Ginisortamab 2000 mg
Serious events: 1 serious events
Other events: 6 other events
Deaths: 0 deaths
Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D
Serious events: 1 serious events
Other events: 7 other events
Deaths: 0 deaths
Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D
Serious events: 2 serious events
Other events: 8 other events
Deaths: 0 deaths
Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D
Serious events: 2 serious events
Other events: 7 other events
Deaths: 0 deaths
Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D
Serious events: 5 serious events
Other events: 8 other events
Deaths: 1 deaths
Part B: Ginisortamab 500 mg + TFD/TPI SoC
Serious events: 4 serious events
Other events: 9 other events
Deaths: 0 deaths
Part B: Ginisortamab 1000 mg + TFD/TPI SoC
Serious events: 2 serious events
Other events: 4 other events
Deaths: 0 deaths
Part B: Ginisortamab 2000 mg + TFD/TPI SoC
Serious events: 4 serious events
Other events: 8 other events
Deaths: 0 deaths
Part C: Ginisortamab 500 mg + mFOLFOX6 SoC
Serious events: 5 serious events
Other events: 5 other events
Deaths: 0 deaths
Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC
Serious events: 1 serious events
Other events: 3 other events
Deaths: 1 deaths
Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC
Serious events: 2 serious events
Other events: 7 other events
Deaths: 1 deaths
Serious adverse events
| Measure |
Part A: Ginisortamab 100 mg
n=3 participants at risk
Participants received ginisortamab monotherapy 100 milligrams (mg) as an intravenously (iv) infusion every 2 weeks (Q2W) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 250 mg
n=5 participants at risk
Participants received ginisortamab monotherapy 250 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 500 mg
n=5 participants at risk
Participants received ginisortamab monotherapy 500 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 1000 mg
n=6 participants at risk
Participants received ginisortamab monotherapy 1000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 2000 mg
n=6 participants at risk
Participants received ginisortamab monotherapy 2000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D
n=8 participants at risk
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (60-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D
n=8 participants at risk
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (30-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D
n=8 participants at risk
Participants received ginisortamab monotherapy 3000 mg as an iv infusion (90-minute infusion) every 3 weeks (Q3W) on Day 1 of each 21-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D
n=8 participants at risk
Participants received ginisortamab monotherapy 4000 mg as an iv infusion (120-minute infusion) every 4 weeks (Q4W) on Day 1 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 500 mg + TFD/TPI SoC
n=9 participants at risk
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with orally administered trifluridine/tipiracil (TFD/TPI) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 1000 mg + TFD/TPI SoC
n=4 participants at risk
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 2000 mg + TFD/TPI SoC
n=8 participants at risk
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 500 mg + mFOLFOX6 SoC
n=5 participants at risk
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC
n=3 participants at risk
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC
n=7 participants at risk
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Infections and infestations
Liver abscess
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Pneumonia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Sepsis
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Injury, poisoning and procedural complications
Overdose
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Injury, poisoning and procedural complications
Toxicity to various agents
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Musculoskeletal and connective tissue disorders
Sacral pain
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Renal and urinary disorders
Urogenital fistula
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
40.0%
2/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
1/3 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Cardiac disorders
Myocardial infarction
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Large intestine perforation
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Large intestinal obstruction
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Hepatobiliary disorders
Biliary obstruction
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Urosepsis
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Vascular device infection
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer pain
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary hypertension
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Vascular disorders
Embolism
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Abdominal pain lower
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Intestinal obstruction
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
General disorders
Pyrexia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Abdominal infection
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Lower respiratory tract infection
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Neutropenic sepsis
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Staphylococcal bacteraemia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Cardiac disorders
Tachycardia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Mallory-Weiss syndrome
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
General disorders
Catheter site thrombosis
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Injury, poisoning and procedural complications
Humerus fracture
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Nervous system disorders
Cerebrovascular accident
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
1/3 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Nausea
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Lower respiratory tract infection bacterial
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Peritonitis bacterial
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
Other adverse events
| Measure |
Part A: Ginisortamab 100 mg
n=3 participants at risk
Participants received ginisortamab monotherapy 100 milligrams (mg) as an intravenously (iv) infusion every 2 weeks (Q2W) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 250 mg
n=5 participants at risk
Participants received ginisortamab monotherapy 250 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 500 mg
n=5 participants at risk
Participants received ginisortamab monotherapy 500 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 1000 mg
n=6 participants at risk
Participants received ginisortamab monotherapy 1000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A: Ginisortamab 2000 mg
n=6 participants at risk
Participants received ginisortamab monotherapy 2000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D
n=8 participants at risk
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (60-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D
n=8 participants at risk
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (30-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D
n=8 participants at risk
Participants received ginisortamab monotherapy 3000 mg as an iv infusion (90-minute infusion) every 3 weeks (Q3W) on Day 1 of each 21-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D
n=8 participants at risk
Participants received ginisortamab monotherapy 4000 mg as an iv infusion (120-minute infusion) every 4 weeks (Q4W) on Day 1 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 500 mg + TFD/TPI SoC
n=9 participants at risk
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with orally administered trifluridine/tipiracil (TFD/TPI) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 1000 mg + TFD/TPI SoC
n=4 participants at risk
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part B: Ginisortamab 2000 mg + TFD/TPI SoC
n=8 participants at risk
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 500 mg + mFOLFOX6 SoC
n=5 participants at risk
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC
n=3 participants at risk
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC
n=7 participants at risk
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Metabolism and nutrition disorders
Vitamin D deficiency
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
22.2%
2/9 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
50.0%
2/4 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
50.0%
3/6 • Number of events 4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
2/8 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
40.0%
2/5 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
1/3 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Cardiac disorders
Arrhythmia supraventricular
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Musculoskeletal and connective tissue disorders
Limb discomfort
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Cardiac disorders
Palpitations
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
2/8 • Number of events 5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
55.6%
5/9 • Number of events 12 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
75.0%
6/8 • Number of events 14 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
60.0%
3/5 • Number of events 11 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
1/3 • Number of events 5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
28.6%
2/7 • Number of events 4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Blood and lymphatic system disorders
Iron deficiency anaemia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Blood and lymphatic system disorders
Leukocytosis
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Blood and lymphatic system disorders
Lymphopenia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Blood and lymphatic system disorders
Neutropenia
|
33.3%
1/3 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
55.6%
5/9 • Number of events 14 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
75.0%
3/4 • Number of events 17 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
37.5%
3/8 • Number of events 8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
1/3 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
28.6%
2/7 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
22.2%
2/9 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
2/8 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Eye disorders
Dry eye
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Oesophageal haemorrhage
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Eye disorders
Eye pain
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Abdominal discomfort
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
2/8 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
22.2%
2/9 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
50.0%
2/4 • Number of events 4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
42.9%
3/7 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
2/8 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
22.2%
2/9 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Abnormal faeces
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Aorto-oesophageal fistula
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
2/6 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
22.2%
2/9 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
50.0%
4/8 • Number of events 4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
60.0%
3/5 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
66.7%
2/3 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
28.6%
2/7 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
66.7%
4/6 • Number of events 7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
2/8 • Number of events 4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
3/9 • Number of events 6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
50.0%
2/4 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
2/8 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
60.0%
3/5 • Number of events 4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
66.7%
2/3 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
28.6%
2/7 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
40.0%
2/5 • Number of events 5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Epigastric discomfort
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Eructation
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Food poisoning
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Gastritis
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
33.3%
1/3 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Melaena
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Mouth ulceration
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Nausea
|
33.3%
1/3 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
40.0%
2/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
40.0%
2/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
66.7%
4/6 • Number of events 4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
2/8 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
2/8 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
66.7%
6/9 • Number of events 12 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
50.0%
2/4 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
50.0%
4/8 • Number of events 6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
100.0%
5/5 • Number of events 5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
57.1%
4/7 • Number of events 4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Obstruction gastric
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Urosepsis
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Oesophageal stenosis
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Stomatitis
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
66.7%
2/3 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Toothache
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Gastrointestinal disorders
Vomiting
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
2/6 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
2/8 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
55.6%
5/9 • Number of events 6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
50.0%
2/4 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
80.0%
4/5 • Number of events 7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
General disorders
Chest pain
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
General disorders
Chills
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
General disorders
Fatigue
|
33.3%
1/3 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
60.0%
3/5 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
50.0%
3/6 • Number of events 8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
2/6 • Number of events 4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
37.5%
3/8 • Number of events 4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
62.5%
5/8 • Number of events 6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
37.5%
3/8 • Number of events 4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
55.6%
5/9 • Number of events 8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
50.0%
2/4 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
2/8 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
40.0%
2/5 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
1/3 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
71.4%
5/7 • Number of events 6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
General disorders
Feeling cold
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
General disorders
Influenza like illness
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
General disorders
Mucosal inflammation
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
General disorders
Oedema peripheral
|
66.7%
2/3 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
General disorders
Peripheral swelling
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
General disorders
Pyrexia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
2/8 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
2/8 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
3/9 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Hepatobiliary disorders
Hepatomegaly
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Hepatobiliary disorders
Hypertransaminasaemia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Hepatobiliary disorders
Portal vein thrombosis
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Immune system disorders
Drug hypersensitivity
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Abdominal infection
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
COVID-19
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Candida infection
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Cellulitis
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Infection
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Lower respiratory tract infection
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Oral candidiasis
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
22.2%
2/9 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Pneumonia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Sinusitis
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Sinusitis bacterial
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Vaginal infection
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Infections and infestations
Vascular device infection
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Injury, poisoning and procedural complications
Craniofacial fracture
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Injury, poisoning and procedural complications
Humerus fracture
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
37.5%
3/8 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
22.2%
2/9 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
50.0%
2/4 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
40.0%
2/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
Amylase increased
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
Aspartate aminotransferase
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
2/6 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
2/6 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
37.5%
3/8 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
2/8 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
3/9 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
50.0%
2/4 • Number of events 4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
40.0%
2/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
2/8 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
2/8 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
40.0%
2/5 • Number of events 5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
3/9 • Number of events 4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
50.0%
2/4 • Number of events 4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
Blood creatine phosphokinase increased
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
Blood creatinine increased
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
Blood lactate dehydrogenase increased
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
2/8 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
Blood phosphorus decreased
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
Blood triglycerides increased
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
C-reactive protein increased
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
Ejection fraction decreased
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
Electrocardiogram QT prolonged
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
Electrocardiogram T wave amplitude decreased
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
Gamma-glutamyltransferase
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
Gamma-glutamyltransferase increased
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
2/8 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
2/8 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
50.0%
2/4 • Number of events 5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
40.0%
2/5 • Number of events 4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
International normalised ratio increased
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
Lipase increased
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
Lymphocyte count decreased
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
Neutrophil count decreased
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
22.2%
2/9 • Number of events 4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
50.0%
4/8 • Number of events 7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
42.9%
3/7 • Number of events 4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
Platelet count decreased
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
2/8 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
28.6%
2/7 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
Prothrombin time prolonged
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
Weight decreased
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
2/8 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
28.6%
2/7 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Investigations
White blood cell count decreased
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
62.5%
5/8 • Number of events 11 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Metabolism and nutrition disorders
Decreased appetite
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
2/6 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
2/8 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
66.7%
6/9 • Number of events 7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
37.5%
3/8 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
60.0%
3/5 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
71.4%
5/7 • Number of events 5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Metabolism and nutrition disorders
Hyperlipidaemia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Metabolism and nutrition disorders
Hypertriglyceridaemia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Metabolism and nutrition disorders
Hyperuricaemia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
22.2%
2/9 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Metabolism and nutrition disorders
Hypophagia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Metabolism and nutrition disorders
Hypophosphataemia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Metabolism and nutrition disorders
Iron deficiency
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Musculoskeletal and connective tissue disorders
Osteoporosis
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
22.2%
2/9 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Musculoskeletal and connective tissue disorders
Pathological fracture
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Musculoskeletal and connective tissue disorders
Synovial cyst
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer pain
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Nervous system disorders
Balance disorder
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Nervous system disorders
Brain oedema
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Nervous system disorders
Cold dysaesthesia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Nervous system disorders
Dizziness
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
22.2%
2/9 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Nervous system disorders
Dysgeusia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Nervous system disorders
Headache
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Nervous system disorders
Hypoaesthesia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Nervous system disorders
Lethargy
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
22.2%
2/9 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
40.0%
2/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Nervous system disorders
Memory impairment
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Nervous system disorders
Neuropathy peripheral
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
28.6%
2/7 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Nervous system disorders
Neurotoxicity
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
40.0%
2/5 • Number of events 6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Nervous system disorders
Parosmia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
1/3 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Nervous system disorders
Syncope
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Nervous system disorders
Taste disorder
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Psychiatric disorders
Depressed mood
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Psychiatric disorders
Depression
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Psychiatric disorders
Hallucination, auditory
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Renal and urinary disorders
Chromaturia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Renal and urinary disorders
Dysuria
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Vascular disorders
Vena cava thrombosis
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Renal and urinary disorders
Hydronephrosis
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Renal and urinary disorders
Hydroureter
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Renal and urinary disorders
Pollakiuria
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Renal and urinary disorders
Proteinuria
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Reproductive system and breast disorders
Balanoposthitis
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Reproductive system and breast disorders
Prostatitis
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Reproductive system and breast disorders
Pruritus genital
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Respiratory, thoracic and mediastinal disorders
Aspiration
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
60.0%
3/5 • Number of events 3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
1/3 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Respiratory, thoracic and mediastinal disorders
Upper-airway cough syndrome
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Skin and subcutaneous tissue disorders
Dermatitis acneiform
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
2/8 • Number of events 2 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Skin and subcutaneous tissue disorders
Dermatitis diaper
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
14.3%
1/7 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Skin and subcutaneous tissue disorders
Rash papular
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
25.0%
1/4 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Vascular disorders
Deep vein thrombosis
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
16.7%
1/6 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Vascular disorders
Embolism
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Vascular disorders
Hypertension
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/9 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
12.5%
1/8 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
33.3%
1/3 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
|
Vascular disorders
Hypotension
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/5 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/6 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
11.1%
1/9 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/4 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/8 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
20.0%
1/5 • Number of events 1 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/3 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
0.00%
0/7 • From Baseline up to End of the Study (up to 3.8 years)
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: GT60